FibroGen discusses financial performance and future plans

to update any forward-looking statements after this call. In the call, CEO Thane Wettig discussed the company's performance in the fourth quarter of 2024. He highlighted key achievements and areas for future growth. The company has been making progress with its collaborations with AstraZeneca and Astellas, which are expected to enhance their research and development efforts. CFO David DeLucia provided details on FibroGen's financial results for the year. He noted that revenues have shown improvement and the company is focused on managing costs. This prudent financial management will support the company’s ongoing projects and initiatives. The executives emphasized the importance of upcoming clinical trials and regulatory milestones. They believe these will be crucial for advancing their product pipeline. There is optimism about future results that could benefit patients and generate revenue. The call concluded with a question-and-answer session, where analysts sought clarification on specific points. The executives welcomed inquiries and provided further insights on their strategies moving forward.